Inactive Instrument

Stentys Stock price

Equities

STNT

FR0010949404

Medical Equipment, Supplies & Distribution

Dynamic Chart
Stentys S.A. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
STENTYS S.A. Announces Revenue Results for the First Quarter Of 2020 CI
Stentys Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2019 CI
Stentys S.A. Announces Revenue Results for the First Quarter 2019 CI
Stentys Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Stentys S.A. Announces Audited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2018 CI
STENTYS S.A. Announces Consolidated Revenue Results for the Third Quarter and Nine Months Ended September 30, 2018 CI
STENTYS Announces Earnings Results for the Six Months Ended June 30, 2018 CI
STENTYS S.A. Announces Unaudited Consolidated Revenue Results for the Second Quarter and First Half of 2018 CI
STENTYS S.A. completed the acquisition of Minvasys. CI
STENTYS S.A. Reports Revenue Results for the First Quarter Ended March 31, 2018 CI
STENTYS S.A. Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2017 CI
STENTYS S.A. entered into an exclusive negotiations agreement to acquire Minvasys for €7.4 million. CI
STENTYS S.A. Announces Unaudited Revenue Results for the Fourth Quarter and Full Year of 2017 CI
STENTYS S.A. Announces the Pre-Commercialization of SERPENTIS, Its New Latest-Generation of Active Stent CI
More news
Managers TitleAgeSince
Chief Executive Officer 74 10-11-18
Public Communications Contact - 14-02-28
Sales & Marketing - 18-06-30
Members of the board TitleAgeSince
Chief Executive Officer 74 10-11-18
Director/Board Member 63 14-02-02
Director/Board Member 68 17-03-30
More insiders
Stentys SA is a French-based company specialized in the development of a new generation of stents for the treatment of acute myocardial infarction or coronary artery disease. It's main product STENTYS Stent, self-expanding coronary bare-metal stent system, is indicated for the treatment of Acute Coronary Syndrome. The Company's institutional shareholders are Sofinnova Partners, Credit Agricole Private Equity and Scottish Equity Partners. In June 2014, it acquired Cappella Peel Away Inc.
More about the company
  1. Stock
  2. Equities
  3. Stock Stentys - Euronext Paris